Matches in Nanopublications for { ?s ?p "[These agents, including the Bruton tyrosine kinase (BTK) inhibitor PCI-32765, display an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug deprivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_assertion description "[These agents, including the Bruton tyrosine kinase (BTK) inhibitor PCI-32765, display an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug deprivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181031.RAQtUklX2WKCozB0z-HIaydjlqoiy2I8Rff7Rh6vd0Wak130_provenance.
- NP687838.RACFzjhJFNRV_DCRS6U7P6BwmGt5nGCzWV7e9BJX0Q9Go130_assertion description "[These agents, including the Bruton tyrosine kinase (BTK) inhibitor PCI-32765, display an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug deprivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687838.RACFzjhJFNRV_DCRS6U7P6BwmGt5nGCzWV7e9BJX0Q9Go130_provenance.
- NP397272.RAm1h3tCRLH4_d3ZZU8JkUYTfPVE9Xs20XQqyPB5QsAP0130_assertion description "[These agents, including the Bruton tyrosine kinase (BTK) inhibitor PCI-32765, display an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug deprivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP397272.RAm1h3tCRLH4_d3ZZU8JkUYTfPVE9Xs20XQqyPB5QsAP0130_provenance.
- assertion description "[These agents, including the Bruton tyrosine kinase (BTK) inhibitor PCI-32765, display an unexpected response in patients with chronic lymphocytic leukemia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis, which is reversible upon temporary drug deprivation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.